<DOC>
	<DOC>NCT00120536</DOC>
	<brief_summary>The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.</brief_summary>
	<brief_title>Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Not currently on drug therapy for type 2 diabetes Blood glucose criteria must be met Body mass index (BMI) in the range 2245 History of type 1 diabetes Evidence of significant diabetic complications Serious cardiovascular events within the past 6 months Laboratory value abnormalities as defined by the protocol Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>